https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.509Great...

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.509

Great post.
I’ve been looking at oncolytic virus articles, and I’m in no doubt that results will improve even further with higher doses. Below a couple of excerpts, the second one from an article by Yuman Fong. Relating to dosage levels, or combination therapy.
As far as I know, the only approved oncolytic virus ( TVec), is intratumoral injection. Efficacy in IV administration, when confirmed with enough data , will be HUGE NEWS.

The link above is to an ASCO article, 2022, regarding MV - NIS, a measles virus, in a trial in bladder cancer, promising early results, but again, applied topically( direct into the bladder) . It is the most recent publication of interest I have found . I did discuss this earlier, after the Endpoints webinar was seen.
I’ve found nothing comparable with CF 33 , with regard to its trials into MULTIPLE tumours.

1. One major concern of oncolytic virus therapy has been that the efficacy may be diminished by the presence of circulating antibodies.An unfavorable effect of circulating antibodies was well documented in a clinical trial using oncolytic measles virus (MV-NIS) in patients with multiple myeloma.70 In this dose escalation study, it was only after the dosing level reached a very high dose of 1011 TCID50 that intravenous infusion with MV-NIS showed efficacy.

2. In addition to direct cell lysis, oncolytic viruses also rely on activation of anti-tumor immunity for their efficacy.3,4 It is therefore not surprising that oncolytic viruses show better efficacy when combined with other therapeutics that are known to avert immune suppression, such as the immune checkpoint inhibitors (ICIs).